Pancreatic Cancer Research

ResearcherJiangsu Province HospitalNo recent work listed

Pengfei Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8660-3464; OpenAlex author ID A5030498698. Sources: OpenAlex.

Their work

Papers
7
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper

Papers 7

  1. CircSTX6 promotes pancreatic ductal adenocarcinoma progression by sponging miR-449b-5p and interacting with CUL2. Co-author DOI 10.1186/s12943-022-01599-5↗
  2. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  3. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  4. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  5. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer. Co-author DOI 10.1111/jcmm.15718↗
  6. LncRNA KCNK15-AS1 inhibits pancreatic cancer progression by promoting the expression of its binding protein ACTR3B Co-author DOI 10.21203/rs.3.rs-55282/v1↗
  7. LncRNA BANCR Promotes Pancreatic Cancer Tumorigenesis via Modulating MiR-195-5p/Wnt/β-Catenin Signaling Pathway. Co-author DOI 10.1177/1533033819887962↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qun Chen · 6 shared papers, 2020–2022 · strength 0.65
  2. Kuirong Jiang · 6 shared papers, 2019–2022 · strength 0.64
  3. Lingdong Meng · 5 shared papers, 2020–2022 · strength 0.56
  4. Zipeng Lu · 5 shared papers, 2019–2021 · strength 0.51
  5. Hao Yuan · 4 shared papers, 2020–2022 · strength 0.46
  6. Peng Shen · 4 shared papers, 2020–2022 · strength 0.46
  7. Wanli Ge · 4 shared papers, 2020–2022 · strength 0.45
  8. Xumin Huang · 4 shared papers, 2020–2021 · strength 0.43
  9. Guodong Shi · 4 shared papers, 2019–2022 · strength 0.40
  10. Taoyue Yang · 3 shared papers, 2021–2022 · strength 0.36
  11. Yi Miao · 3 shared papers, 2020–2021 · strength 0.32
  12. Yi Miao · 3 shared papers, 2019–2022 · strength 0.31
  13. Baobao Cai · 3 shared papers, 2019–2021 · strength 0.29
  14. Min Tu · 2 shared papers, 2020–2022 · strength 0.23
  15. Shouji Cao · 2 shared papers, 2020 · strength 0.19
  16. Meng Cao · 2 shared papers, 2019–2020 · strength 0.17
  17. Tianfang Xia · 2 shared papers, 2019–2020 · strength 0.17
  18. Lei Chen · 2 shared papers, 2019–2020 · strength 0.17
  19. Pengbo Zhang · 2 shared papers, 2019–2020 · strength 0.17
  20. Xinquan Wu · 2 shared papers, 2019–2020 · strength 0.17
  21. Kuirong Jiang · 1 shared paper, 2020 · strength 0.10
  22. Lei Xu · 1 shared paper, 2020 · strength 0.09
  23. Jingjing Zhang · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.